- Guide to PHARMACOLOGY
Synonyms: AMG 139 | AMG-139 | MEDI2070
Compound class: Antibody
Comment: Brazikumab (AMG 139, MEDI2070) is a fully human anti-IL23A monoclonal antibody in clinical development for autoimmune indications.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent WO2011056600 .
|No information available.|
|Summary of Clinical Use|
|Phase 1 clinical trials evaluating brazikumab as a monotherapy in mild to severe Crohn's disease (NCT01258205) and moderate to severe psoriasis (NCT01094093) have been completed. Phase 2 trials in subjects with active, moderate to severe Crohn's disease are ongoing (see NCT02574637 and NCT01714726).|
|Mechanism Of Action and Pharmacodynamic Effects|
|IL-23 is a potent inducer of pro-inflammatory cytokines including IL-6, IL-17, TNFα, IL-22 and GM-CSF. IL-23 is the key driver in autoimmune/inflammatory disease [1-2]. As such anti-IL-23 antibodies (targeting the p19 subunit unique to IL-23; IL23A) are being developed to ameliorate the effects of IL-23 related diseases or disorders. Such agents would be expected to inhibit IL-23 signaling, IL-23 activation of Th17 cells, IL-23 activation of NK cells, or production of proinflammatory cytokines.|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT01094093||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis||Phase 1 Interventional||Allergan|
|NCT01258205||Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects||Phase 1 Interventional||Allergan|
|NCT01714726||Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.||Phase 2 Interventional||Allergan|
|NCT02574637||Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease||Phase 2 Interventional||Allergan|